Healthcare dividend stocks – my purchase in August

The Healthcare sector is the lowest weighted sector in my my dividend stock Portfolio this week. I own two healthcare dividend stocks (PFE & JNJ) and my last healthcare purchase added to my position in PFE in June this year. I’ve picked some other stocks from the Dividends Champion List that caught my eye to see how they compare and if starting a new position to diversify further is worthwhile.

Here’s my portfolio as of 24-August grouped by market sector. Healthcare is the lowest sector this week followed by the Utilities and Consumer Cyclical sectors. AT 8.9% healthcare is outside my +/- 10% of average value rule.

My portfolio as of 24-Aug-2014, grouped by sector showing the Healthcare sector as lowest weight with 8.9%, followed by Utilities and Consumer Cyclical.
My portfolio as of 24-Aug-2014, grouped by sector showing the Healthcare sector as lowest weight with 8.9%, followed by Utilities and Consumer Cyclical.

My healthcare dividend stocks

I currently positions in JNJ & PFE in the Healthcare sector.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) is a $290B healthcare company that is diversified company operating in three segments: Pharmaceutical, Medical Devices & Diagnostics and Consumer.

JNJ is one of the top 20 dividend champions with a 52 year history. Its TTM payout ratio is 49.5, and overall the Payout Ratio has been declining from its peak of 64.6 reached in 2011. Current dividend yield is 2.7% with an annualized 5 year dividend growth of 7.4%.

Its P/E of 19 is lower than the industry average of 21.9 but higher than the S&P 500 average of 18.2. With exceptions in 2009 and 2010, its P/E ratio has generally been higher than the S&P average but the P/E has held steady at 19 since 2013. 5 year estimated EPS growth is 7%.

Pfizer (PFE)

Pfizer (PFE) is one of the world’s largest pharmaceutical companies with a market cap of $183B.

PFE has increased its dividends yearly for the last 4 years, having cut them in 2010. It has a dividend yield of 3.6% with a TTM payout ratio of 63%. Over the last 5 years, the P/O ratio has averaged 67% so it’s just a little lower at present. The dividend has increased at a 5 year annual growth rate of 5.4%.

PFE has a current P/E of 18.2, matching the S&P’s average of 18.2 and beating the industry average of 21.9. Its P/E value has held steady since 2013. Except for 2009, PFE has always had a higher P/E than the S&P average since 2005. 5 year EPS growth is estimated at 3.1%.

Choosing new stocks to consider

My initial screening of the Dividends Champion List is as follows:

  • Include only stocks from Champions, Challengers and Contenders filtered by the sector I’m interested in
  • Exclude any stock which has had negative growth in the last 1 or 5 years
  • Exclude any stock which is projected to have negative growth in the next 5 years
  • Include only stocks with a dividend yield above 2%

There were only 3 companies meeting the above criteria and one of them was JNJ that I already own. I’ve listed the other two below as well as adding NHC which bypassed the filter on account not having a growth estimate in the champion list.

The new contenders shortlist

I don’t own any of the following three companies; I included them to see how they compare to what I own and if they might be worthwhile purchases.

National Healthcare Corp (NHC)

National Healthcare Corp (NHC) is a small cap $813M company that operates more than 130 long-term health care centers, homecare programs and independent / assisted living communities in 11 states.

It’s a dividend contender, having increased dividends for 11 years. The current dividend yield is 2.3% with a good 37% TTM Payout Ratio that has been in the 30-40% range for the last 6 years. The annualized dividend growth over the last 5 years has been 5.6%.

The company has a P/E of 16.5 which compares well with the S&P’s average of 18.2. The P/E has been generally been lower than the S&P’s average each year except for 2006, 2008 and 2012. I couldn’t find an estimated 5 year EPS growth on either FinViz, S&P Capital or Morningstar, so for this review I went with 5.6% which is the historical 5 year growth.

Owens & Minor (OMI)

Owens & Minor (OMI) is a $2B distributor of medical / surgical supplies to the healthcare industry. It reports in two operating segments; Domestic and International with 90% of its revenue coming from the Domestic segment.

OMI has increased its dividend payment for the last 17 years. It offers a current yield of 2.9% that has grown at an annual rate of 10% over the last 5 years. Its TTM payout ratio is 60%, a number which has been steadily increasing from 32% in 2008.

Its P/E ratio of 21.2 is above the industry average of 30.1 as well as the S&P’s 18.2. Since 2005, the P/E has been higher than the S&P average except for 2008 and it reached a high of 26 in 2006. Estimated 5 year EPS growth is 6%.

Baxter International (BAX)

Baxter International (BAX) is a $40B pharmaceutical company with a focus on treating blood and circulatory illnesses. It operates in two segments: BioScience and , Medical Products. The BioScience division will be spun-off into a standalone company next year.

BAX has an 8 year dividend growth history with a 2.7% yield. The dividend has grown at an annual rate of 15.6% over the last 5 years. Its payout ratio, while good, has been trending higher since 2011, with a current TTM value of 56. The average P/O over the last 5 years was 40%.

The P/E value is 21.1 which is lower than the industry average of 34.5 and higher than the S&P average of 18.2. Apart from a record P/value in 2004 where the P/E reached 55, BAX’s P/E has generally been higher than the S&P. The current level marks a higher difference than the S&P over the previous 3 years. Estimated EPS growth over the next 5 years is 8%.

For more information on Baxter see Dividend Mantra’s great review of BAX from June.

Honorable mentions

Abbott Labs (ABT)

Abbott Labs (ABT) is a former dividend champion with a 41 year track record of increasing dividends. However due to the AbbVie spin-off, it was removed from the Dividend Champion list at the end of 2012 and I expect to see it show up again in a few more years.

United Healthcare (UNH)

United Healthcare (UNH) is also on my watchlist, however they don’t qualify for this roundup due to their dividend yield which is less than 2%.

Vanguard Healthcare ETF (VHT)

Because of the smaller selection of dividend champions in the healthcare sector, I am considering to purchase shares in the Vanguard Healthcare ETF (VHT). This has a low expense ratio of 0.14% and can be bought commission-free. It contains 311 stocks from the healthcare sector, although its distribution is around 1.3%. The annual distribution and low yield are the main factors stopping me here.

What to buy?

Looking at all 5 choices, my criteria of requiring a 5 year dividend growth history eliminates my current holdings in PFE from the start. PFE lowered dividends in 2009 but has been increasing them ever since so it should appear on the dividend champion list soon as a Challenger.

The remaining 4 companies all have suitable dividend yield and meet my criteria requiring a 3% dividend growth rate. Dividend yield between the 4 companies ranges from 2.3 to 2.9 with OMI being the most generous.

NHC scores the lowest of the 4 due to its lower yield, smaller size and inconsistent dividend schedule. It gained points for having the lowest payout ratio of all 4 companies.

BAX is in third place, having higher growth and a reasonable current yield; however its score is lowered by a shorter dividend growth history as well as an inconsistent dividend schedule.

OMI is in second place, helped by a longer dividend growth history, higher current yield and a stable dividend payment schedule. It loses some points due to its smaller market cap.

In first place, then its JNJ with a 52 year dividend growth history that outclasses the other companies in this roundup. In addition it has a reasonable payout ratio that’s the second lowest of the 5 companies, and a solid dividend increase schedule.

So I’ve decided to buy more JNJ this week. I would lean towards a non-pharmaceutical company for any additional purchases in this sector, but I’m not convinced of either OMI or NHC to purchase either right now.

Here’s the outcome visually.

Yield #Yr DivGr5 EstGr5 Projected Stable Score Status
JNJ 2.7 52 7.4 7.1 17 5 44 Buy
OMI 2.9 17 10.3 6.0 18 5 35 Buy
BAX 2.7 8 15.6 8.0 17 2 28 Buy
NHC 2.3 11 5.6 5.6 14 2 26 Buy
PFE 3.6 4 5.4 3.1 21 5 0 Hold

My purchases this week

So total purchases this week will be:

  • $424 Individual Stocks (JNJ)

This purchase should increase my yearly dividend income by about $11.

Full disclosure: I am long PFE & JNJ.

 

Quote of the day

Be careful about reading health books. You may die of a misprint.

0 thoughts on “Healthcare dividend stocks – my purchase in August”

  1. Hi DL, love your post. I’m fond of Baxter, but have not bought any yet. I used to work in a hospital and we had plenty of Baxter’s stuff and it was quality.

    Have you looked into Smith and Nephew? I do not own them either but I am fond of them too.

    Thanks again for a look into this sector, very interesting to look at things that I’ve not ever heard of before like OMI, despite having worked with lots of products in the hospital.

    Cheerio!

    1. Hi M,
      No unfortunately I haven’t heard of Smith and Nephew – I just looked them up and they have a 1 year dividend growth so my screener missed them.

      My screener’s quite near-sighted really – not many stocks make it past a 2% dividend and a 5 year dividend growth history.

      I’m glad you found the post useful; I like to highlight companies on the dividend champion list and though I don’t cover them in detail; hopefully they spark some further research.

      Cheers!
      -DL

    1. Hi PIP,
      Thanks, I’ll certainly be adding MDT to my watchlist; they have a 36 year dividend history and a low payout ratio so are definitely worth considering. They didn’t pass my screener as their yield is under 2% but hopefully with a price drop or dividend increase they’ll get there.

      I appreciate your comments as always!
      Best wishes,
      -DL

  2. DL,

    Thanks for the mention! Much appreciated.

    I think JNJ is a great pick. It’s my personal favorite in the healthcare sector. Can’t go wrong with 50+ years of dividend increases and a strong likelihood of another 50.

    Best wishes!

    1. Hi DM,
      You’re welcome! Your stock analyses are always great and well worth reading!

      Yes JNJ passed its Golden Dividend Anniversary and is working on its Diamond Dividend Anniversary which is just amazing.

      Cheers!
      -DL

    1. Hey Henry,

      No I’ve not heard of them before – do you own any of their stock? I see they have an 11 year dividend growth which is great, but their dividend yield is too low for me at less than 1%. So I’d want to wait for the yield to increase.

      Remember to wear a helmet when longboarding!
      Best wishes!
      -DL

      1. Yep, I’m a shareholder in MLAB. Bought a small position like two years ago. Never added more since their stock hasn’t been at attractive valuations since then.

        And yes, I’ll make sure to wear a helmet. I haven’t fallen yet, but I plan to eventually.

        Cheers.

  3. If there is any sector that will weather most storms in the future, then I’d predict that to be healthcare because at least in Western countries the demand is bound to keep going up and up.
    There is a large variety of companies for you to choose from it seems from the list. I guess most of them won’t really do anything too radical, but long term (slow) growth should be reasonable to expect.

    1. Hi Kristi,
      Yes that’s certainly true, there will always be a need for healthcare.

      Drug companies do have a lot of risks, considering the cost of developing & testing a new drug, paying damages over lawsuits, and patent expiry allowing cheaper generic drugs. But the payoff can be huge if a new drug is found.

      In the US, healthcare insurance is a little uncertain because of the impacts of the Affordable Care Act aren’t fully understood but I’m sure the insurance industry will find a way to continue to make a profit no matter what happens.

      One area I think should be fairly sustainable and somewhat steady would be retirement / senior care centers.

      Thanks for your comments, I appreciate you stopping by.

      Best wishes,
      -DL

  4. JNJ is a great stock and one of my long term holdings. In the health space you might want to look at BDX, BCR and ABT/ABBV too. Thanks for sharing.

Leave a Reply

Your email address will not be published. Required fields are marked *